Advertisement

Immunophenotypical Subtype of Childhood T-All with Favourable Outcome in the COALL 1985–1992 Study Group

  • T. Niehues
  • P. Kapaun
  • D. Harms
  • H. Kabisch
  • S. Burdach
  • G. Janka-Schaub
  • U. Göbel
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

Physiologically, T-cell differentiation involves passage through the thymic cortex, where approximately 90% of the T-cells will be eliminated by apoptosis. This thymic cortical T-cell population is called selection-related (SR) and can be identified by a distinct pattern of surface marker expression (CD1+CD4+8+).

Aims of the study: as malignant transformation can occur at different stages of T-cell differentiation we asked the following questions:
  1. 1.

    What percentage of T-ALL cases are of SR phenotype?

     
  2. 2.

    Does SR phenotype confer a different prognosis under standard leukemia therapy?

     

Keywords

Acute Lymphoblastic Leukemia Mediastinal Mass Leukemic Blast Childhood Acute Lymphoblastic Leukemia Myeloid Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Haynes BF (1991) Ontogeny of T cell precursors: a model for the initial stages of human T cell development. Immunology Today 10:87–91CrossRefGoogle Scholar
  2. 2.
    Porcelli SA (1995) The CD1 family: a third lineage of antigen presenting molecules. Adv Immunol 59:1–98 (1995)Google Scholar
  3. 3.
    Janka GE, Winkler K, Göbel U, Graubner U, Gutjahr P Haas, RJ, Jürgens H, Spaar H for the CO-ALL study group (1988) Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. Leukemia 2:73–78Google Scholar
  4. 4.
    Janka GE, Göbel U, Graubner U, Haas RJ, Jürgens H, Spaar H, Winkler K for the COALL study group (1990) Improved prognosis for childhood acute lymphoblastic leukemia with very high blood count (003E100/nl) with rotation of non cross-resistant drug combinations. Hematol Blood Transf 33:489–492Google Scholar
  5. 5.
    Harma D, Spaar HJ, Jorch N, Graubner U, Siegert E, Göbel U, Janka-Schaub GE for the COALLStudy Group (1997) Randomized comparioson of 6-mercaptopurine (6-MP) vs. 6-thioguanine (6-TG) in maintenace treatment of childhood acute lyphoblastic leukemia (ALL): Differing hematological toxicity. Manuscript in preparation.Google Scholar
  6. 6.
    Kisielow P, von Boehmer H (1995) Development and selection of T cells: Facts and puzzles. Adv Immunol 58:57–209Google Scholar
  7. 7.
    Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF (1980) Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA 77: 1588–92PubMedCrossRefGoogle Scholar
  8. 8.
    Campana D, van Dongen JJM, Mehta A, Coustan-Smith E, Wolvers-Tettero ILW, Ganeshaguru K, Janossy G (1991) Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 77: 1546–1554PubMedGoogle Scholar
  9. 9.
    Roper M, Crist WM, Metzger R, Ragab AH, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD (1983) Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 61: 830–7PubMedGoogle Scholar
  10. 10.
    Grist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE (1988) Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A pediatric oncology group study. Blood 72: 1891–7Google Scholar
  11. 11.
    Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner G, Riehm H (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and consultations of the multicenter trial ALL-BFM 86. Blood 84: 3122–33PubMedGoogle Scholar
  12. 12.
    Pui C-H, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC (1990) Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75: 174–9PubMedGoogle Scholar
  13. 13.
    Shuster JJ, Falletta JM, Pullen J, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M (1990) Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group study. Blood 75: 166–73PubMedGoogle Scholar
  14. 14.
    Greaves MF (1986) Differentiation-linked leukemogenesis in lymphocytes. Science 234: 697–703PubMedCrossRefGoogle Scholar
  15. 15.
    Pui C-H, Behm FG, Crist WM (1993) Clinical and Biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82: 343–62PubMedGoogle Scholar
  16. 16.
    Hurwitz CA, Mirro J (1990) Mixed-lineage leukemia and asynchronous antigen expression. Hematology/Oncology Clinics of North America 4: 767–794PubMedGoogle Scholar
  17. 17.
    Andjelic S, Drappa J, Lacy E, Elkon KB, Nikoliczugic J (1994) The onset of Fas-expression parallels the acquisition of CD4 and CD8 in fetal and adult ab thymocytes. Int Immunol 6:73–80PubMedCrossRefGoogle Scholar
  18. 18.
    Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:57477Google Scholar
  19. 19.
    Thiel E, Kranz BR, Raghavachar A, Bartram CR, Löffler H, Messerer D, Ganser A, Ludwig W-D, Büchner T, Hoelzer D (1989) Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and it’s clinical significance within adult acute lymphoblastic Leukemia. Blood 73: 1247–58PubMedGoogle Scholar
  20. 20.
    Garand R, Voisin S, Papin S, Praloran V, Lenormand B, Favre M, Philip P, Bernier M, Vanhaecke D, Falkenrodt A, Bene MC, Faure G and the Groupe d’Etude Immunologique des leucemies (1993) Characteristics of pro-T-ALL subgroups: comparison with late T-ALL. Leukemia 7:161–7PubMedGoogle Scholar
  21. 21.
    Ferrara F, Cimino R, Antinolfi I, de Rosa C, Mele G, Mettivier V, Fusco C, del Vecchio L (1992) Clinical relavance of immunological dissection in T-ALL: a report on 20 cases with stem cell (CD7+, CD4-, CD8-, CD1) phenotype. Amer J Hematol 40: 98–102CrossRefGoogle Scholar
  22. 22.
    Uckun FM, Steinherz PG, Sather H, Arthur D, Trigg M, Tubergen D, Reaman G, Gaynon P (1996) Improved outcome of children with T-lineage acute lymphoblastic leukemia after intensive chemotherapy. Blood 88 (Suppl. 1): 2656Google Scholar
  23. 23.
    Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Faith Uckun, Ungerleider R (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14: 18–24PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • T. Niehues
    • 1
  • P. Kapaun
    • 2
  • D. Harms
    • 2
  • H. Kabisch
    • 2
  • S. Burdach
    • 1
  • G. Janka-Schaub
    • 2
  • U. Göbel
    • 1
  1. 1.Dept. of Pediatric HematologyGermany
  2. 2.Depts. of OncologyUniversities of Düsseldorf and HamburgGermany

Personalised recommendations